1,10-phenanthroline has been researched along with Prostatic Hyperplasia in 1 studies
1,10-phenanthroline: RN given refers to parent cpd; inhibits Zn-dependent metalloproteinases
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishii, K | 1 |
| Usui, S | 1 |
| Sugimura, Y | 1 |
| Yoshida, S | 1 |
| Hioki, T | 1 |
| Tatematsu, M | 1 |
| Yamamoto, H | 1 |
| Hirano, K | 1 |
1 other study available for 1,10-phenanthroline and Prostatic Hyperplasia
| Article | Year |
|---|---|
Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion.
Topics: Amino Acid Sequence; CD13 Antigens; Copper; Dose-Response Relationship, Drug; Edetic Acid; Egtazic A | 2001 |